---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123252"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:45:37.697359+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim

## Summary
- GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.
- R&D expenses fell to $26.5M from $45.8M YoY; cash $162.6M sufficient into Q1 2026.
- Evorpacept ASPEN-06 Phase 2 gastric/GEJ cancer showed 40.3% ORR vs 26.6% control; median duration 15.7 months.
- CFO Peter Garcia resigns effective Nov 8; Shelly Pinto (SVP Finance, CAO) appointed interim CFO.
- Upcoming milestones: Phase 3 registrational trial for evorpacept in gastric/GEJ mid-2025; SABCS breast cancer Dec 12.

## SEC filing metadata
- accession: 0000950170-24-123252
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/0000950170-24-123252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/alxo-20241105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123252
- JSON: https://secwatch.observer/filing/0000950170-24-123252.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123252.txt

## Key facts
- Executive change
  Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/0000950170-24-123252-index.htm
- Executive change
  Shelly Pinto was appointed as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
  - Action: appointed
  - Role: Interim Chief Financial Officer
  source text: On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017024123252/0000950170-24-123252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.